Product/Composition:- | Nirmatrelvir + Ritonavir |
---|---|
Strength:- | Nirmatrelvir(150 mg) + Ritonavir(100 mg) |
Form:- | Tablet |
Reference Brands:- | Paxlovid®(US & EU- For Emergency Use Authorization) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Paxlovid® (Nirmatrelvir + Ritonavir) is a key oral antiviral for high-risk COVID-19 patients, approved in the US, EU, and many global markets. Each 5-day pack includes Nirmatrelvir 150 mg + Ritonavir 100 mg tablets. PharmaB2B platforms connect buyers with verified suppliers offering Paxlovid and generic versions for bulk procurement, institutional tenders, and international distribution—ensuring regulatory compliance and fast delivery.
Nirmatrelvir + Ritonavir, branded as Paxlovid®, is a leading oral antiviral approved in the US, EU, and globally for treating mild to moderate COVID-19 in high-risk adults. Paxlovid combines Nirmatrelvir 150 mg (2 tablets) with Ritonavir 100 mg (1 tablet), taken twice daily for 5 days. Available in convenient blister packs, it is in high demand for hospitals and COVID-19 programs. Through trusted PharmaB2B platforms, buyers can source Paxlovid or generic equivalents from verified manufacturers, ensuring regulatory compliance, competitive pricing, and global logistics. Partner with reliable suppliers for seamless bulk procurement and international distribution.